NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their RightsApril 27, 2026
Share Twitter Facebook LinkedIn Email The company has been working through a major restructuring that includes a large-scale divestment program to free up funds and shore up its coffers.Read More